IP Library Granted Patent US 6,900,225
Granted Patent B2
US 6,900,225 · App. 10/275,972 · Granted May 31, 2005

Quinolonecarboxylic acid derivative

Assignee: Daiichi Pharmaceutical Co., Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,900,225
App. No.
10/275,972
Granted
May 31, 2005
Kind
B2
Abstract

(−)-7-[(7S)-7-Amino-5-azaspiro[2.4]heptan-5-yl]-6-fluoro-1-[(1R, 2S)-2-fluoro-1-cyclopropyl]-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid.1HCl.1H 2 O and antibacterial compositions containing this compound. The compound of the present invention exhibits not only excellent antibacterial activity and safety, but also remarkable stability against light and humidity, and is thus useful as an antibacterial agent.

Claims (6)

1. A compound represented by the following formula (1)

2. A compound as claimed in claim 1 , which assures crystals exhibiting characteristic peaks in the vicinity of angles of diffraction (2θ) of 6.9, 10.5, 14.4, 23.1, 26.9, and 27.8(°) when subjected to powder X-ray diffractometry.

3. A solid antibacterial composition containing a compound represented by the following formula (1) together with a pharmaceutically acceptable carrier

4. A solid antibacterial composition as claimed in claim 3 , wherein the compound of formula (1) assumes crystals exhibiting characteristic peaks in the vicinity of angles of diffraction (2 θ) of 6.9, 10.5, 14.4, 23.1, 26.9, and 27.8(°) when subjected to powder X-ray diffractometry.

5. A method for the treatment of bacterial infection in a mammal or fish, which comprises administering to said mammal or fish an effective amount of a compound represented by the following formula (1)

6. The method as claimed in claim 5 , wherein the compound of formula (1) assumes crystals exhibiting characteristic peaks in the vicinity of angles of diffraction (2 θ) of 6.9, 10.5, 14.4, 23.1, 26.9, and 27.8(°) when subjected to powder X-ray diffractometry.

Assignments (2)
CONFIRMATION OF EXCLUSIVE PATENT LICENSE Recorded Sep 9, 2003
From: DAIICHI PHARMACEUTICAL CO., LTD.
To: PFIZER INC.
Reel/Frame 014462/0343 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 31, 2003
From: TAKEMURA, MAKOTO; TAKAHASHI, HISASHI; KAWAKAMI, KATSUHIRO; ITOH, MASAO; SUZUKI, TETSUYA; OHTANI, TSUYOSHI; SEKIGUCHI, MASAYASU; MIYAUCHI, RIE; HAYAKAWA, ISAO
To: DAIICHI PHARMACEUTICAL CO., LTD.
Reel/Frame 013902/0758 →
Continuity (1)
Related Publication 20030187008A1 · Oct 2, 2003